Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Exegenesis Bio

News headline image
US FDA Grants Orphan Drug Designation to EXG110, a Novel Gene Therapy for Fabry Disease
From Exegenesis Bio
Via Business Wire
News headline image
Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without External Assistance
From Exegenesis Bio
Via Business Wire
News headline image
Exegenesis Bio To Present Five Posters at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, Los Angeles, CA, May 16-20, 2023
From Exegenesis Bio
Via Business Wire
News headline image
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
From Exegenesis Bio
Via Business Wire
News headline image
Exegenesis Bio Appoints Mahen Gundecha Chief Business Officer
From Exegenesis Bio
Via Business Wire
News headline image
Exegenesis Bio Opens Philadelphia and Boston Offices and Announces Expansion Plans
From Exegenesis Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.